Cancer of the Breast

Fowble, Barbara; Bevan, Alison; Alvarado, Michael; Melisko, Michelle

doi:10.1016/b978-1-4160-5897-7.00059-7

Cited by 3 publications

(2 citation statements)

References 1,003 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its usage is widespread in tailoring individualized treatment plans. 21 Patients with high recurrence scores may derive greater advantage from adjuvant chemotherapy in comparison to those in the other groups, while those in the low-risk group may not require chemotherapy. 21 Data have recently been published in support of the use of the Oncotype assay in patients with node-positive disease.…”

Section: Discussionmentioning

confidence: 99%

“…21 Patients with high recurrence scores may derive greater advantage from adjuvant chemotherapy in comparison to those in the other groups, while those in the low-risk group may not require chemotherapy. 21 Data have recently been published in support of the use of the Oncotype assay in patients with node-positive disease. 22 In patients with node-positive disease who received chemotherapy and hormonal therapy, the Recurrence Score (RS) was found to be more accurate in predicting recurrence than standard pathologic staging features such as tumor size and lymph node involvement.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Should the Breast Cancer Staging System be Revised?

Sanli,

Tekcan Sanli,

Aydogan

et al. 2023

The American Surgeon™

View full text Add to dashboard Cite

Objective The purpose of this study was to determine whether breast cancer patients at stage T2N0 with tumor size ≥4 cm and <4 cm. Method Patients with T2N0 stage breast cancer diagnosed between 2010 and 2019 were analyzed in 2 groups as <4 cm (T2a) and ≥4 cm (T2b) in the study using the SEER 17 Research Plus database. The patients’ clinicopathological characteristics and oncological outcomes were included. Group comparisons of prognostic factors, overall survival (OS), and cancer-specific survival (CSS) were made. Results In this study, which involved 70971 patients, the T2a group had higher 5-year OS rate (87.2 ± .2 vs 80.8 ± .5%) and 5-year CSS rate (93.7 ± .1% vs 89.4 ± .4%) than the T2b group ( P < .001). Univariate analysis revealed that the overall risk of death was 1.5 times higher in T2b than T2a (HR: 1.533 [95% CI: 1.450-1.622], P < .001), whereas multivariate analysis demonstrated the risk was 1.4 times higher (HR: 1.384 [95% CI: 1.307-1.466], P < .001). The risk of cancer-specific death was 1.7 times higher in univariate analysis (HR: 1.691 [95% CI: 1.561-1.832], P < .001) and 1.4 times higher in multivariate analysis (HR: 1.420 [95% CI: 1.309-1.541], P < .001). Conclusion Overall survival and BCSS rates in stage T2b breast cancer patients are significantly lower than in T2a patients. Tumor size ≥4 cm in breast cancer is a negative predictor of prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%